Literature DB >> 12894858

Racial background is a determinant factor in the maintenance dosage of warfarin.

Gin Gin Gan1, Alan Teh, Kim Yen Goh, Heng Thay Chong, Kang Wah Pang.   

Abstract

Warfarin is a drug commonly used in the prevention of thromboembolic events. There have been reports suggesting that racial background may influence warfarin dose requirements. Malaysia is a multiracial country in which there are 3 major races, Malay, Chinese, and Indian. We examined 100 patients from our hospital on stable maintenance doses of warfarin, with international normalized ratio (INR) of 2.0 to 3.5. We found that the mean warfarin dose for Indian patients (n = 19) was 6.9 mg, for Chinese patients (n = 55) was 3.6 mg, and for Malay patients (n = 26) was 3.2 mg. The results showed that the Indian patients required a statistically significantly higher warfarin dose than did patients of the other 2 races (P < .0005). Age was also found to affect the daily warfarin maintenance dose.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12894858     DOI: 10.1007/bf02983247

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  8 in total

1.  Factors determining the maintenance dose of warfarin in Chinese patients.

Authors:  H C Yu; T Y Chan; J A Critchley; K S Woo
Journal:  QJM       Date:  1996-02

2.  Differences in plasma binding of drugs between Caucasians and Chinese subjects.

Authors:  H H Zhou; A Adedoyin; G R Wilkinson
Journal:  Clin Pharmacol Ther       Date:  1990-07       Impact factor: 6.875

3.  Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0.

Authors:  A Blann; J Hewitt; F Siddiqui; D Bareford
Journal:  Br J Haematol       Date:  1999-10       Impact factor: 6.998

4.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

Authors:  G P Aithal; C P Day; P J Kesteven; A K Daly
Journal:  Lancet       Date:  1999-02-27       Impact factor: 79.321

Review 5.  Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

Authors:  J A Goldstein
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

6.  Factors affecting the maintenance dose of warfarin.

Authors:  A H James; R P Britt; C L Raskino; S G Thompson
Journal:  J Clin Pathol       Date:  1992-08       Impact factor: 3.411

7.  Effect of age upon the induction and maintenance of anticoagulation with warfarin.

Authors:  J R Gladman; G Dolan
Journal:  Postgrad Med J       Date:  1995-03       Impact factor: 2.401

Review 8.  Pharmacogenetics of warfarin elimination and its clinical implications.

Authors:  H Takahashi; H Echizen
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

  8 in total
  16 in total

1.  Genetic polymorphism of the CYP2C9 subfamily of 3 different races in warfarin maintenance dose.

Authors:  Gin Gin Gan; Maude Elvira Phipps; Chee Seng Ku; Alan Teh; Vijaya Sangkar
Journal:  Int J Hematol       Date:  2004-10       Impact factor: 2.490

2.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.

Authors:  Nihat Ozer; Nese Cam; Burak Tangurek; Songul Ozer; Huseyin Uyarel; Dilaver Oz; Mehmet Rasit Guney; Figen Ciloglu
Journal:  Heart Vessels       Date:  2010-03-26       Impact factor: 2.037

Review 3.  The future prospects of pharmacogenetics in oral anticoagulation therapy.

Authors:  Farhad Kamali; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

4.  Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.

Authors:  N S Bazan; N A Sabry; A Rizk; S Mokhtar; O A Badary
Journal:  Ir J Med Sci       Date:  2013-06-27       Impact factor: 1.568

5.  Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?

Authors:  J H S You; F W H Chan; R S M Wong; G Cheng
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

6.  Prediction of biogeographical ancestry from genotype: a comparison of classifiers.

Authors:  Elaine Y Y Cheung; Michelle Elizabeth Gahan; Dennis McNevin
Journal:  Int J Legal Med       Date:  2016-12-20       Impact factor: 2.686

7.  An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population.

Authors:  Dhakchinamoorthi Krishna Kumar; Deepak Gopal Shewade; Marie-Anne Loriot; Philippe Beaune; B V Sai Chandran; Jayaraman Balachander; Chandrasekaran Adithan
Journal:  Eur J Clin Pharmacol       Date:  2014-12-19       Impact factor: 2.953

8.  Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans.

Authors:  Wenndy Hernandez; Keston Aquino-Michaels; Katarzyna Drozda; Shitalban Patel; Young Jeong; Harumi Takahashi; Larisa H Cavallari; Minoli A Perera
Journal:  Transl Res       Date:  2014-11-22       Impact factor: 7.012

9.  Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.

Authors:  Stuart A Scott; Lisa Edelmann; Ruth Kornreich; Robert J Desnick
Journal:  Am J Hum Genet       Date:  2008-01-17       Impact factor: 11.025

10.  Warfarin maintenance dose prediction for Chinese after heart valve replacement by a feedforward neural network with equal stratified sampling.

Authors:  Weijie Ma; Hongying Li; Li Dong; Qin Zhou; Bo Fu; Jiang-Long Hou; Jing Wang; Wenzhe Qin; Jin Chen
Journal:  Sci Rep       Date:  2021-07-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.